| 02/01 | Analysis-GSK gives few clues on plans to replenish medicine cabinet | RE |
| 02/01 | GSK profit grows as aims for first-ever approved RSV vaccine | AN |
| 01/31 | Coeptis Therapeutics Partners With University of Pittsburgh to Advance Cell Therapy Dev.. | MT |
| 01/31 | IQVIA Signs Collaboration Deal With Alibaba Cloud in China | MT |
| 01/31 | IQVIA Collaborates With Alibaba Cloud to Provide Commercial, Clinical Solutions in Chin.. | MT |
| 01/31 | IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in.. | CI |
| 01/30 | Moderna's Wins Breakthrough Therapy Designation from US FDA for Investigational Syncyti.. | MT |
| 01/30 | Moderna's mRNA Vaccine Candidate for Respiratory Syncytial Virus Gets Breakthrough Ther.. | MT |
| 01/30 | Moderna Gets FDA Breakthrough Designation for RSV Vaccine Candidate | DJ |
| 01/30 | Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational .. | CI |
| 01/27 | Insider Sell: Moderna | MT |
| 01/27 | Intron Health Lowers Price Target on Lonza Group, Maintains Hold Recommendation | MT |
| 01/27 | Insider Sell: Seagen | MT |
| 01/26 | FDA advisers back the same COVID vaccine for initial shots, boosters | RE |
| 01/26 | Moderna's Reported Plan to Increase COVID-19 Vaccine Price Raised Concerns From US Sena.. | MT |
| 01/26 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/25 | Cowen Adjusts Price Target on Moderna to $150 From $130, Maintains Market Perform Ratin.. | MT |
| 01/25 | Berenberg Adjusts Price Target on Seagen to $170 From $183, Maintains Buy Rating | MT |
| 01/25 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/25 | Lonza Group AG Provides Earnings Guidance for the Year 2023 | CI |
| 01/25 | Lonza Group Seeks Mergers and Acquisitions | CI |
| 01/25 | Transcript : Lonza Group AG, 2022 Earnings Call, Jan 25, 2023 | CI |
| 01/25 | Lonza Sweetens Shareholder Returns After COVID-19-related Sales Peak Drives 2022 Result.. | MT |
| 01/25 | Lonza Shares Fall But Regain Ground Following 2022 Result | DJ |
| 01/25 | European shares slip as investors weigh earnings reports | RE |
| 01/25 | Lonza's 2022 Core Earnings and Sales Increased; Plans a Share Buyback | DJ |
| 01/25 | Lonza Group Profit Balloons 80% in 2022 Amid 15% Increase in Sales
| MT |
| 01/25 | Lonza underscores growth prospects with share buy-back, dividend hike | RE |
| 01/25 | Swiss Manufacturer Lonza Plans CHF2 Billion Buyback On SIX Swiss Exchange | MT |
| 01/25 | Switzerland's Lonza Affirms Mid-term FY24 Outlook As 2022 Sales Climb 15% | MT |
| 01/25 | Lonza Group AG Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 01/25 | Lonza Group AG announces an Equity Buyback for CHF 2,000 million worth of its shares. | CI |
| 01/25 | Lonza Group AG authorizes a Buyback Plan. | CI |
| 01/24 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/24 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/24 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/24 | Morgan Stanley Adjusts Moderna Price Target to $205 From $209, Maintains Equal Weight R.. | MT |
| 01/24 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/23 | SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $143 From $144, Maint.. | MT |
| 01/23 | U.S. FDA proposes shift to annual COVID vaccine shots | RE |
| 01/23 | U.S. FDA proposes to simplify COVID vaccine strategy | RE |
| 01/23 | Insider Sell: Moderna | MT |
| 01/20 | Insider Sell: Moderna | MT |
| 01/20 | SVB Securities Adjusts Price Target on Seagen to $162 From $160, Maintains Outperform R.. | MT |
| 01/19 | Seagen Gets FDA Accelerated Approval for Colorectal Cancer Drug Tukysa | MT |
| 01/19 | Seagen Gets FDA Accelerated Approval for Tukysa | DJ |
| 01/19 | US FDA Grants Approval to Seagen's Tukysa to Treat Colorectal Cancer | MT |
| 01/19 | Seagen Inc. Announces FDA Approval of Tukysa in Combination with Trastuzumab for People.. | CI |
| 01/19 | Davos 2023: What you need to know about the WEF on Thursday | RE |
| 01/18 | Retail Sales, Producer Price Data Drag Equities Lower | MT |
| 01/18 | Wall St sinks after weak data, hawkish Fed comments | RE |
| 01/18 | Retail Sales, Producer Price Data Drag Equities Lower | MT |
| 01/18 | Wall St closes lower after weak data, hawkish Fed comments | RE |
| 01/18 | Wall St stumbles after weak data, hawkish Fed comments | RE |
| 01/18 | Retail Sales, Producer Price Data Drive US Equities Lower | MT |
| 01/18 | Slumping Treasury Yields Following Lower Retail Sales, Producer Prices Keep US Equity I.. | MT |
| 01/18 | Dow Sinks 350 Points After Retail Sales, Producer Prices Slump More Than Forecast | MT |
| 01/18 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
| 01/18 | Wall Street reverses gains as hawkish Fed officials douse easing inflation cheer | RE |
| 01/18 | SVB Securities Adjusts Price Target on Moderna to $111 From 102, Maintains Market Perfo.. | MT |
| 01/18 | Global markets live: BASF, United Airlines, Microsoft, Pfizer, Apple.. | |
| 01/18 | Chardan Adjusts Moderna's Price Target to $208 From $191, Keeps Neutral Rating | MT |
| 01/18 | Canaccord Genuity Starts Alnylam Pharmaceuticals at Buy With $310 Price Target | MT |
| 01/18 | Sector Update: Health Care Stocks Higher Pre-Bell Wednesday | MT |
| 01/18 | Sector Update: Health Care | MT |
| 01/18 | Moderna CEO Discussed Supply of COVID Vaccines With China | MT |
| 01/18 | Moderna RSV Vaccine Candidate Meets Primary Efficacy Endpoints in Late-Stage Trial -- S.. | MT |
| 01/18 | Trending : Moderna Sees Positive Data in Experimental RSV Vaccine | DJ |
| 01/18 | Davos 2023: Moderna CEO in talks with China to supply COVID vaccines | RE |
| 01/17 | Moderna Says RSV Vaccine Candidate Meets Primary Efficacy Endpoints in Late-Stage Trial.. | MT |
| 01/17 | Moderna Shares Up 4.8% After-Hours on Trial Results for RSV Vaccine | DJ |
| 01/17 | Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, Ha.. | CI |
| 01/17 | Moderna says RSV vaccine 84% effective at preventing symptoms in older adults | RE |
| 01/17 | Barclays Adjusts Price Target on IQVIA Holdings to $260 From $235, Maintains Overweight.. | MT |
| 01/17 | Insider Sell: Moderna | MT |
| 01/16 | Lonza Completes Expansion At US Facility | MT |
| 01/15 | US Health Regulators To Probe Pfizer-BioNTech COVID-19 Shot's Potential Link To Stroke | MT |
| 01/13 | U.S. says Pfizer's bivalent COVID shot may be linked to stroke in older adults | RE |
| 01/13 | Insider Sell: Moderna | MT |
| 01/13 | Baird Adjusts Price Target on IQVIA Holdings to $260 From $266, Maintains Outperform Ra.. | MT |
| 01/12 | AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Add Recommendatio.. | MT |
| 01/11 | Transcript : Lonza Group AG Presents at 41st Annual J.P. Morgan Healthcare Co.. | CI |
| 01/11 | Deutsche Bank Adjusts Moderna's Price Target to $225 From $185, Maintains Buy Rating | MT |
| 01/10 | Sen. Sanders asks Moderna not to hike COVID vaccine price | RE |
| 01/10 | Senator Bernie Sanders Asks Moderna Not to Raise COVID-19 Vaccine's Price | MT |
| 01/10 | US Senator Sanders Asks Moderna to Halt Planned COVID-19 Vaccine Price Increase | MT |
| 01/10 | Pieris Pharmaceuticals Says it Achieves $5 Million Seagen Milestone | MT |
| 01/10 | Sen. Sanders asks Moderna not to hike COVID vaccine price | RE |
| 01/09 | Moderna Mulls Increased Pricing For Commercial Distribution Of COVID-19 Jab | MT |
| 01/09 | Transcript : Seagen Inc. Presents at 41st Annual J.P. Morgan Healthcare Confe.. | CI |
| 01/09 | Transcript : Moderna, Inc. Presents at 41st Annual J.P. Morgan Healthcare Con.. | CI |
| 01/09 | Moderna Reportedly Mulling $110 to $130 Price Range for COVID-19 Shot | MT |
| 01/09 | Moderna Looks for Potential Approval of 2 new Vaccines in 2023, CEO Stephane Bancel Say.. | MT |
| 01/09 | Moderna Meets Guidance for 2022 COVID-19 Vaccine Sales, Reiterates 2023 Target | MT |
| 01/09 | Moderna considers pricing COVID vaccine at $110-$130 - WSJ | RE |
| 01/09 | Moderna to Consider Price of $110 to $130 for Covid.. | MT |
| 01/09 | Moderna considers pricing COVID vaccine at $110-$130 - WSJ | RE |
| 01/09 | Moderna Considers Price Of $110-$130 For Covid-19 Vaccine - WSJ | RE |
| 01/09 | Transcript : Alnylam Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morga.. | CI |
| 01/09 | Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron... | |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
